News

Home

News

Technology

Careers

Company

Contact

Our CEO Shunnichi Kashida will give an expert talk at the 7th RNA-Targeted Drug Discovery & Development Summit.

We are coming to BIO-EUROPE.

We will be presenting at the 28th EFMC International Symposium on Medicinal Chemistry (September 1-5, 2024, Rome, Italy).

xFOREST Therapeutics Achieves A Milestone in Drug Discovery Collaboration with Takeda.

xFOREST Therapeutics to be certified as a "J-Startup KANSAI" by Kansai Bureau of Economy, Trade and Industry

CEO Shunichi Kashida delivered a keynote speech and participateed in a panel discussion at the 6th RNA-Targeted Drug Discovery & Development Summit in Boston.

We gave an oral presentation and poster presentation at the 40th Medicinal Chemistry Symposium (MCS2023).

Emi Miyashita received Outstanding Poster Award at the 50th International Symposium on Nucleic Acids Chemistry (ISNAC2023).

We participated in the EU-Japan Biotech & Pharma Partnering Conference 2023.

Yasutoshi Nishimura, Minister of Economy, Trade and Industry, visited our laboratory.

CEO Shunichi Kashida participated as a panelist at the 28th International RNA Society meeting.

CEO Shunichi Kashida delivered a lecture at the 445th lecture meeting of the Chem-Bio Informatics Society.

CEO Shunichi Kashida has been featured in the CiRA Newsletter.

Otsuka Enters Collaboration with xFOREST Therapeutics on RNA Structure-Targeted Drug Discovery Covering Multiple Diseases

We've been awarded a Innovative Technology Grant Program (Monozukuri Hojokin)

xFOREST Therapeutics, Axcelead DDP and Kyowa Kirin Initiated an Collaboration in RNA Structures Targeted Drug Discovering

We received the EMBO Reports Award at the 22nd Annual Meeting of the RNA Society of Japan

Our CTO, Kaoru Komatsu, published a paper on fluid flow-dependent mRNA degradation mechanism in Nature Communications.

xFOREST Therapeutics Announces Drug Discovery Collaboration with Daiichi Sankyo to Target RNA Structures in Multiple Diseases

xFOREST Therapeutics to be certified as a "A rank company" by Kyoto City Venture Companies Evaluation Committee

Our CTO Kaoru Komatsu and CEO Shunichi Kashida published a paper on the basics of FOREST technology

We've been awarded grant from New Energy and Industrial Technology Development Organization (NEDO)

xFOREST Therapeutics Announces Drug Discovery Collaboration with Takeda to Target RNA Structures in Neurological Diseases

xFOREST Announces Closing of Seed Funding Round

We've been awarded a grant from Kyoto city

xFOREST Therapeutics Announces Research Collaboration with Tohoku University

xFOREST Therapeutics Announces Research Collaboration with Center for iPS Cell Research and Application, Kyoto University

We started our company, "xFOREST Therapeutics Co., Ltd."

We've joined start-up accelerator program "Open Network Lab BioHealth 2nd batch" by Digital Garage.

We've been awarded "KYOTO Entrepreneurship Development Program 2019"

Kaoru Richard KOMATSU (Chairman of the board, CTO) got Best Award in Bayer x Sysmex -Pitch Your Dreams in KOBE2019-

We've been awarded Incubation Funding by Kyoto University

Page updated

Report abuse